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To the Editor
A novel coronavirus named COVID-19 has begun to spread in
Wuhan, China from December 2019 and become a global health con-
cern.1 Individuals with underlying diseases are at greater risk and
more prone to be critically ill in case of infection so that mortality
rate is 49% in subjects entering intensive care units.2 It has been
reported that critically ill COVID-19 patients remarkably have ele-
vated levels of pro-inflammatory cytokines including IL-6, G-CSF,
IP10, MCP1, MIP1A, and TNFa, contributing to outbreak of cytokine
storm.3 These turn of events lead to acute respiratory distress syn-
drome and ultimately maybe death2 and glucocorticoids were not
efficient in reducing rate of mortality.4
It has been suggested that mesenchymal stem cell (MSC) trans-
plantation could be considered as a beneficial approach in treatment
many disease. MSC exerts its positive impacts through immunomo-
dulation and differentiation stimulation.5 It has proposed that patho-
gen molecules such as double-stranded RNA in virus is able to
increase induction of toll-like receptors (TLRs) on MSC resulting in
manifestation of immunomodulatory effects of MSC.6 Darwish et al.
demonstrated that MSC is potentially able to treat H5N1 infection
which has a cytokine profile similar to COVID-19.7 The mechanisms
of action of MSC on COVID-19 treatment schematically are shown on
Fig. 1.
Therefore, MSC therapy potentially could be considered as an effi-
cacious and safe treatment approach in COVID-19-induced pneumo-
nia. In this regard, Leng et al. recently demonstrated that with
perfusion of 1 £ 106 cells per kilogram of weight, almost all the clini-
cal symptoms such as fever, breath shortness, and low oxygen satura-
tion disappeared and the inflammation levels were relieved 2-4 days
after MSC transplantation.8 Moreover, in a critically ill 65 years old
woman, MSC transplantation with 5 £ 107 cells three times resulted
in significant decrease in CRP and increase in CD3+, CD4+ and CD8+ T
cells to the normal ranges. Also, CT images implied to remarkable
relieve in pneumonia.9 Furthermore, there are 30 registered studies
investigating MSC therapy on COVID-19 to explore whether MSC
transplantation could be able to shed the light in COVID-19 treat-
ment. A summary of characteristics of registered studies are pre-
sented in Table 1.
Author contribution
Masoud Khorshidi: Conceptualiation, Investigation, Methodology,
Software, Visualization; Meysam Zarezadeh: Data curation, Investiga-
tion, Validation, Visualization, Writing - original draft, Writing -
review and editing; Mohammadreza Emami: Data curation, Visuali-
zation; Beheshteh Olang: Data curation, Visualization, Validation;
Omid Moradi Moghaddam: Conceptualization, Project administra-
tion, Supervision, Visualization.
* Corresponding author at: Trauma and Injury Research Center, Critical Care Medi-
cine Department, Iran University of Medical Sciences, Shahid Hemmat Highway, Teh-
ran, Iran.
** Corresponding author at: Ph.D. of Nutritional Sciences, School of Nutrition and
Food Sciences, Tabriz University of Medical Sciences, Attar-Neishaburi St., Golgasht
Alley, Azadi Blvd., Tabriz, Iran.
E-mail addresses: zarezadehm@tbzmed.ac.ir (M. Zarezadeh),
moradimoghadam@yahoo.com (O.M. Moghaddam).
https://doi.org/10.1016/j.hrtlng.2020.08.007
0147-9563/© 2020 Elsevier Inc. All rights reserved.
Heart & Lung 49 (2020) 745748
Contents lists available at ScienceDirect
Heart & Lung
journal homepage: www.heartandlung.com
